RA0806

antibody from Oursmab

Targeting: TYRP1 b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP

Western blot (Supportive data in Antibodypedia)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0806

Provider

Oursmab

Product name

Flanvotumab (Biosimilar Reference Antibody) (TYRP1)

Antibody type

Monoclonal

Description

Flanvotumab (also known as IMC-20D7S) is an investigational, fully human monoclonal antibody developed for the treatment of melanoma. It is designed as a targeted immunotherapy that specifically binds to a differentiation antigen expressed on melanoma cells. The proposed mechanism of action involves the antibody binding to its target on the tumor cell surface, which may then recruit immune effector cells (such as natural killer cells or macrophages) through antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) to eliminate the cancer cells. It represents a strategy to direct the immune system specifically against antigen-positive melanoma cells.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Flanvotumab (Biosimilar Reference Antibody) (TYRP1)-RA0806-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.